OGT announces the release of new Genefficiency™ RNA Sequencing Service
Oxford Gene Technology (OGT), provider of innovative genetics research and biomarker solutions to advance molecular medicine, has today announced the release of its new Genefficiency™ RNA Sequencing (RNA-Seq) Service. Taking advantage of OGT’s experience in optimised sequencing project design and advanced data analysis, this new service overcomes the need for expensive and time-intensive in-house bioinformatics analysis, and has a wide range of other benefits. To ensure that researchers obtain informative data, OGT provides expert assistance throughout the duration of the project, from the initial stages of experimental design all the way through to the final results. In addition, the results are presented in an easy-to-use, interactive report that makes the final expression analysis as fast and straightforward as possible. By taking care of the complexity of sample and data processing, the new service makes RNA-Seq a widely accessible tool for revealing the complexities of the transcriptome.
RNA-Seq allows much broader discoveries at the transcriptome level than many other approaches. It provides the experimental freedom to identify unknown genes and isoforms without having to wait for new versions of exon or custom arrays and genome annotation updates. Analysis of the data generated allows new information to be revealed, such as changes in transcript activity and variant analysis. Additional analysis can reveal more in-depth knowledge on alternative splice junctions, allele-specific expression and the identification of fusion proteins.
OGT’s Chief Executive Officer, Dr Mike Evans, commented: “Whilst RNA-Seq is a powerful and flexible technology, considerable challenges are presented in terms of the data analysis process. Our optimised pipeline has been specifically designed to help researchers quickly and easily overcome these obstacles, while our purpose-built interactive reporting tool delivers meaningful, accurate publication-ready results for researchers”.
OGT’s intuitive reporting tool allows the quick and effective interrogation of data. The results can be quickly and efficiently examined against a number of parameters, such as differentially expressed genes. Furthermore, researchers can instantly investigate distinct isoforms for specified genes in order to determine those that are significantly contributing to differential expression at the individual gene-level.
As a comprehensive and fully integrated service, advice and consultation is provided as standard throughout the whole process. The initial experimental design is fully customisable in order to meet study objectives, with OGT advising on aspects such as the correct combination of starting material and sequencing depth. Rigorous quality control metrics are used to confirm that reliable, parsimonious, well-mapped reads are informing downstream analysis. Once the data report is received, a complimentary consultation with an OGT bioinformatician allows the researcher to maximise the potential power of the reporting tool. In this way, the depth of value provided by the new Genefficiency™ RNA-Seq Service ensures that researchers will quickly generate biological insight from their gene expression research project.
For further information, please contact:
Oxford Gene Technology, Begbroke Science Park, Begbroke Hill, Woodstock Road, Begbroke, Oxfordshire, OX5 1PF, U.K.
T: +44 (0) 1865 856826 ; F: +44 (0) 1865 848684 ; E: firstname.lastname@example.org
Notes for editors:
About Oxford Gene Technology
Founded by Professor Ed Southern, Oxford Gene Technology (OGT) provides innovative genetics research and biomarker solutions to advance molecular medicine. The company has two trading businesses: Genomics comprises of CytoSure™ cytogenetics array, labelling and interpretation software products and services for the detection of chromosomal abnormalities, and Genefficiency™ Genomic Services, a unique combination of platforms, expertise and processing capabilities to deliver rapid, relevant genomic data. The Biomarkers business utilises proprietary next generation technologies to build a rich patent-protected portfolio of promising biomarkers for early stage cancer detection including advanced programmes in colorectal and prostate cancer plus the autoimmune disease systemic lupus erythematosus.
CytoSure™ and Genefficiency™ NGS browser: For Research Use Only; Not for Use in Diagnostic Procedures
CytoSure: This product is provided under an agreement between Agilent Technologies, Inc., and OGT. The manufacture, use, sale or import of this product may be subject to one or more of U.S. patents, pending applications, and corresponding international equivalents, owned by Agilent Technologies, Inc. The purchaser has the non-transferable right to use and consume the product for RESEARCH USE ONLY AND NOT for DIAGNOSTICS PROCEDURES. It is not intended for use, and should not be used, for the diagnosis, prevention, monitoring, treatment or alleviation of any disease or condition, or for the investigation of any physiological process, in any identifiable human, or for any other medical purpose.